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Introduction/aim
The recent advances in the surgical treatment (more pre-
cise diagnostic features, new surgical devices, advance-
ment in intensive care) allowed in the last 15 years an
extension of surgical indication to a liver resection to a
larger population of patients also in the elderly. Aim of
this work is to evaluate the indication and limits of the
surgical treatment of colorectal liver metastases in the eld-
erly.
Patients and methods
Between April 2002 and January 2008 we had 108 admis-
sions and performed a liver resection for colorectal liver
metastases, and we treated 287 colorectal liver metastases
on 99 patients. In 57 resections the patient was >65 years
old (Group A) (range 66–83 yrs.) while the remnants
were till 65 years old (Group B) (range 40–65). We regis-
tered: type of resection, postoperative complications, day
of discharge and survival-rate of both groups. We per-
formed such a variety of liver resections in this collective
of patients by referring to Brisbane terminology. In all the
patients an R0 resection was achieved by intraoperative
biopsy of the resected specimen's margin (Figure 1), and
eventually additional resection in doubtful cases or posi-
tive pathological response.
Results
In Group A, 10 patients showed a minor complication
(grade I–II) (17.5%) and 12 patients a major one (grade
III–V) (21%) while in Group B were respectively 10
(19.6%) and 9(17.6%). In Group A the average postoper-
ative recovery time was 13.5 days (range 6–38), while in
Group B it was 12.08 days (range 5–27). In Group A three
patients (5.2%) died for major complications, while in
Group B we observed 1 perioperative death (~2%). The
survival-rate was similar in both groups; one and three
years overall survival-rate was respectively Group A 68%
and 42% vs Group B 65% and 40%.
Conclusion
About a half of hepatic resections of colorectal liver metas-
tasis are performed in old patient (over 65 years). Our
results suggest that the limits for hepatic resection in the
elderly are the same as for younger patients. In the over 65
years group there is the tendency to perform less major
liver resections in order to achieve the R0-status. The mor-
bidity seems to be comparable in both groups also if the
perioperative mortality is more than doubled in over 65
years patients. The long-term survival-rate is not to corre-
late to the age of the patients, and also major hepatic
resection are relative safe and justified in the elderly in
order to achieve oncological results.
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Pathologic specimen. Atypical resection VI–VII segment: almost 1 cm free-disease margin.Page 2 of 2
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